Abiraterone (Zytiga) is a new generation drug that has proven effectiveness in the fight against such a common pathology as prostate cancer. As a rule, it is not used as a single drug, but in an effective combination with prednisolone or cytotoxic therapy. Produced by the well-known pharmacological concern Cipla Limited (India). Abiraterone (Zytiga) is a complete analogue (generic) of such a well-known drug on the market as Zytiga. Abiraterone (Zytiga) is available in tablet form for oral administration. Each tablet contains the active substance Abiraterone acetate in a fixed dosage of 250 mg. It is an androgen receptor inhibitor, due to which it stops the growth and spread of the tumor to other organs and tissues. Abiraterone (Zytiga) is a targeted drug and is used exclusively for the treatment of malignant neoplasms of the prostate in men of various etiologies. This tool is prescribed in such cases: with diagnosed metastasis to other organs and tissues; in the absence of the possibility of surgical treatment; with the ineffectiveness of previous cytotoxic therapy. It is also not used as a monotherapy drug. It is prescribed simultaneously with prednisolone in the prescribed dosage. The recommended dose of Abiraterone (Zytiga) is 1g or 4 tablets taken 1 time per day 1 hour before or 2 hours after a meal. For oral administration only! The duration of the course of therapy is determined individually by the attending physician, depending on the effectiveness of treatment and other indicators. It is not recommended to interrupt the course of treatment or change the dosage on your own, as this may lead to the ineffectiveness of Abiraterone (Zytiga).